Cargando…

What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients

SIMPLE SUMMARY: Younger age has been associated with better overall survival in Ewing sarcoma, especially under the age of 10. Our study aimed at describing long-term outcomes of a cohort of 60 patients aged 0–10 with Ewing sarcoma, treated with chemotherapy, surgery and/or radiotherapy. Overall sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Bosma, Sarah E., van der Heijden, Lizz, Sierrasesúmaga, Luis, Merks, Hans J. H. M., Haveman, Lianne M., van de Sande, Michiel A. J., San-Julián, Mikel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946787/
https://www.ncbi.nlm.nih.gov/pubmed/35326609
http://dx.doi.org/10.3390/cancers14061456
_version_ 1784674274336833536
author Bosma, Sarah E.
van der Heijden, Lizz
Sierrasesúmaga, Luis
Merks, Hans J. H. M.
Haveman, Lianne M.
van de Sande, Michiel A. J.
San-Julián, Mikel
author_facet Bosma, Sarah E.
van der Heijden, Lizz
Sierrasesúmaga, Luis
Merks, Hans J. H. M.
Haveman, Lianne M.
van de Sande, Michiel A. J.
San-Julián, Mikel
author_sort Bosma, Sarah E.
collection PubMed
description SIMPLE SUMMARY: Younger age has been associated with better overall survival in Ewing sarcoma, especially under the age of 10. Our study aimed at describing long-term outcomes of a cohort of 60 patients aged 0–10 with Ewing sarcoma, treated with chemotherapy, surgery and/or radiotherapy. Overall survival of these youngest patients with ES was very good. After 10 years, 81% of patients were still alive, 89% did not have a local recurrence and 81% did not have distant metastasis (in lungs and/or bone). Limb salvage surgery was achieved in >90% of patients. Wide resection margin was the only factor significantly associated with better survival, but age < 6 years, smaller tumors, no metastases at diagnosis and treatment after 2000 also seemed to result in better overall survival. ABSTRACT: (1) Background: Younger age has been associated with better overall survival (OS) in Ewing sarcoma (ES), especially under the age of 10. The favorable survival in younger patients underlines the need for minimizing treatment burden and late sequelae. Our study aimed at describing clinical characteristics, treatment and outcome of a cohort of ES patients aged 0–10. (2) Methods: In this retrospective multicenter study, all consecutive ES patients aged 0–10, treated in four sarcoma centers in the Netherlands (n = 33) and one in Spain (n = 27) between 1982 and 2008, with a minimum follow-up of 10 years, were included. OS, local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) were calculated. Potential factors of influence on OS (risk and protective factors) were analyzed. (3) Results: 60 patients with median follow-up 13.03 years were included. All patients were treated with chemotherapy in combination with local treatment, being surgery alone in 30 (50%) patients, radiotherapy (RT) alone in 12 (20%) patients or surgery plus RT in 18 (30%) patients (12 pre- and 6 postoperative). Limb salvage was achieved in 93% of patients. The 10-OS, -LRFS and -DMFS are 81% (95% CI: 71–91%), 89% (95% CI: 85–93%) and 81% (95% CI: 71–91%), respectively. Six patients developed LR, of which two developed subsequent DM; all had axial ES (pelvis, spine or chest wall), and these patients all died. Ten patients developed DM; eight died due to progressive disease, and two are currently in remission, both with pulmonary metastasis only. Negative or wide resection margin was significantly associated with better OS. Age < 6 years, tumor volume < 200 mL, absence of metastatic disease and treatment after 2000 showed trends towards better OS. Two patients developed secondary malignancy; both had chemotherapy combined with definitive RT for local treatment. (4) Conclusions: Overall survival of these youngest patients with ES was very good. Limb salvage surgery was achieved in >90% of patients. Wide resection margin was the only factor significantly associated with better survival.
format Online
Article
Text
id pubmed-8946787
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89467872022-03-25 What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients Bosma, Sarah E. van der Heijden, Lizz Sierrasesúmaga, Luis Merks, Hans J. H. M. Haveman, Lianne M. van de Sande, Michiel A. J. San-Julián, Mikel Cancers (Basel) Article SIMPLE SUMMARY: Younger age has been associated with better overall survival in Ewing sarcoma, especially under the age of 10. Our study aimed at describing long-term outcomes of a cohort of 60 patients aged 0–10 with Ewing sarcoma, treated with chemotherapy, surgery and/or radiotherapy. Overall survival of these youngest patients with ES was very good. After 10 years, 81% of patients were still alive, 89% did not have a local recurrence and 81% did not have distant metastasis (in lungs and/or bone). Limb salvage surgery was achieved in >90% of patients. Wide resection margin was the only factor significantly associated with better survival, but age < 6 years, smaller tumors, no metastases at diagnosis and treatment after 2000 also seemed to result in better overall survival. ABSTRACT: (1) Background: Younger age has been associated with better overall survival (OS) in Ewing sarcoma (ES), especially under the age of 10. The favorable survival in younger patients underlines the need for minimizing treatment burden and late sequelae. Our study aimed at describing clinical characteristics, treatment and outcome of a cohort of ES patients aged 0–10. (2) Methods: In this retrospective multicenter study, all consecutive ES patients aged 0–10, treated in four sarcoma centers in the Netherlands (n = 33) and one in Spain (n = 27) between 1982 and 2008, with a minimum follow-up of 10 years, were included. OS, local recurrence-free survival (LRFS) and distant metastasis-free survival (DMFS) were calculated. Potential factors of influence on OS (risk and protective factors) were analyzed. (3) Results: 60 patients with median follow-up 13.03 years were included. All patients were treated with chemotherapy in combination with local treatment, being surgery alone in 30 (50%) patients, radiotherapy (RT) alone in 12 (20%) patients or surgery plus RT in 18 (30%) patients (12 pre- and 6 postoperative). Limb salvage was achieved in 93% of patients. The 10-OS, -LRFS and -DMFS are 81% (95% CI: 71–91%), 89% (95% CI: 85–93%) and 81% (95% CI: 71–91%), respectively. Six patients developed LR, of which two developed subsequent DM; all had axial ES (pelvis, spine or chest wall), and these patients all died. Ten patients developed DM; eight died due to progressive disease, and two are currently in remission, both with pulmonary metastasis only. Negative or wide resection margin was significantly associated with better OS. Age < 6 years, tumor volume < 200 mL, absence of metastatic disease and treatment after 2000 showed trends towards better OS. Two patients developed secondary malignancy; both had chemotherapy combined with definitive RT for local treatment. (4) Conclusions: Overall survival of these youngest patients with ES was very good. Limb salvage surgery was achieved in >90% of patients. Wide resection margin was the only factor significantly associated with better survival. MDPI 2022-03-12 /pmc/articles/PMC8946787/ /pubmed/35326609 http://dx.doi.org/10.3390/cancers14061456 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bosma, Sarah E.
van der Heijden, Lizz
Sierrasesúmaga, Luis
Merks, Hans J. H. M.
Haveman, Lianne M.
van de Sande, Michiel A. J.
San-Julián, Mikel
What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients
title What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients
title_full What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients
title_fullStr What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients
title_full_unstemmed What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients
title_short What Do We Know about Survival in Skeletally Premature Children Aged 0 to 10 Years with Ewing Sarcoma? A Multicenter 10-Year Follow-Up Study in 60 Patients
title_sort what do we know about survival in skeletally premature children aged 0 to 10 years with ewing sarcoma? a multicenter 10-year follow-up study in 60 patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946787/
https://www.ncbi.nlm.nih.gov/pubmed/35326609
http://dx.doi.org/10.3390/cancers14061456
work_keys_str_mv AT bosmasarahe whatdoweknowaboutsurvivalinskeletallyprematurechildrenaged0to10yearswithewingsarcomaamulticenter10yearfollowupstudyin60patients
AT vanderheijdenlizz whatdoweknowaboutsurvivalinskeletallyprematurechildrenaged0to10yearswithewingsarcomaamulticenter10yearfollowupstudyin60patients
AT sierrasesumagaluis whatdoweknowaboutsurvivalinskeletallyprematurechildrenaged0to10yearswithewingsarcomaamulticenter10yearfollowupstudyin60patients
AT merkshansjhm whatdoweknowaboutsurvivalinskeletallyprematurechildrenaged0to10yearswithewingsarcomaamulticenter10yearfollowupstudyin60patients
AT havemanliannem whatdoweknowaboutsurvivalinskeletallyprematurechildrenaged0to10yearswithewingsarcomaamulticenter10yearfollowupstudyin60patients
AT vandesandemichielaj whatdoweknowaboutsurvivalinskeletallyprematurechildrenaged0to10yearswithewingsarcomaamulticenter10yearfollowupstudyin60patients
AT sanjulianmikel whatdoweknowaboutsurvivalinskeletallyprematurechildrenaged0to10yearswithewingsarcomaamulticenter10yearfollowupstudyin60patients